Sera from individuals acutely ill with lobar pneumonia possess the capacity to precipitate in
high titre a non-protein somatic fraction derived from pneumococci (Fraction C). Following …

Broth cultures of hemolytic streptococci derived from patients are capable of rapidly liquefying
normal human fibrin clot. The active fibrinolytic principle is also contained in sterile, cell-…

… By WILLIAM S. TILLETT AND SOL SHERRY (From the Department of Medicine, New
York University College of Medicine, and the Third … Review article for references up to …

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA)
clinical trials that represent both patients' and physicians' priorities. Methods We …

Objective To identify predictors of poorer physical function in established psoriatic arthritis (PsA).
Methods PsA patients with disease duration of ≥10 years were identified from the Bath …

Objective. To evaluate the sensitivity, specificity, and feasibility of the ClASsification criteria
for Psoriatic ARthritis (CASPAR) to retrospectively classify an existing research cohort. …

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features,
which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests …

Objective. Work disability (WD) is an important functional outcome measure in arthritis. There
is a large body of information on WD in rheumatic diseases such as RA and AS; however, …

Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …